Spyre Therapeutics, Inc.
SYRECIK 0001636282 · last filing Jul 2, 2026
Insider signal
trades dated in the last 90 days · non-derivative only
15,834 bought / 30,834 sold
net −15,000 sh · −$2.37M
- buys
- 2
- sells
- 7
- insiders active
- 3
Filing tape
Filed Thu, Jul 2, 2026
- −0 sh · $549.3K
Burrows Scott L — Chief Financial Officer
- Exercised7,500Common Stock@ $14.50→ 105,494 held
- Sold5,775Common Stock@ $87.55→ 99,719 held
- Sold1,725Common Stock@ $88.37→ 97,994 held
- Exercised7,500Stock Option (Right to Buy)→ 352,357 held
- −0 sh · $502.0K
Sloan Sheldon — Chief Medical Officer
- Exercised8,334Common Stock@ $27.46→ 8,334 held
- Sold6,500Common Stock@ $87.52→ 1,834 held
- Sold1,834Common Stock@ $88.34→ 0 held
- Exercised8,334Stock Option (Right to Buy)→ 305,000 held
- −15,000 sh · $1.32M
Turtle Cameron — Chief Executive Officer · Director
- Sold10,176Common Stock@ $87.44→ 587,364 held
- Sold4,234Common Stock@ $88.12→ 583,130 held
- Sold590Common Stock@ $88.91→ 582,540 held
Insiders on this tape
- Burrows Scott LChief Financial Officer
- Sloan SheldonChief Medical Officer
- Turtle CameronChief Executive Officer · Director
Informational data only — not investment advice.
The institutional holdings shown here are aggregated from third-party public regulatory filings (such as SEC Form 13F). These filings are reported with a delay (generally up to 45 days after each quarter-end), are backward-looking, and may exclude short positions, non-U.S. holdings, cash, and other assets. The data may contain errors, omissions, misclassifications, or gaps, and may not reflect a manager's current positions.
All figures are provided on an "as is" basis for general information only. Nothing on this page is financial, investment, or trading advice, a recommendation, or an endorsement of any security, manager, or strategy. Do not rely on it. Independently verify any figure against the original filings and consult a qualified professional before making any financial decision. Your use is subject to our Terms of Service.